Viridian Therapeutics, Inc.

VRDN· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$22.00+0.32%

2026-09-18

Financials

Valuation Metrics

Viridian Therapeutics, Inc.'s Market Cap is $2.49B. At end of 2025 it was $2.64B. Ranked #1880 of 3,121 in US market (top 60%), #696 of 1,463 on NASDAQ (top 48%), #118 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$2.49B	US#1,880/3,121 Sec#118/266
Revenue	$71M	US#2,746/3,121 Sec#137/266
Net Income	$-387M	US—/3,121 Sec—/266
Total Assets	$1.10B	US#2,432/3,121 Sec#97/266
Net Assets	$662M	US#2,056/3,121 Sec#89/266
Value
P/B	3.76x	US#1,958/3,121 Sec#109/266
P/S	35.04x	US#2,894/3,121 Sec#157/266
FCF Yield	-13.44%	US—/3,121 Sec—/266
Profitability
ROE	-58.45%	US#2,716/3,121 Sec#170/266
ROA	-35.27%	US#2,921/3,121 Sec#174/266
Op. Margin	-569.68%	US#2,809/3,121 Sec#156/266
Revenue Growth	23220.33%	US#4/3,121 Sec#2/266
Financial Health
Debt Ratio	65.72%	US#724/3,121 Sec#148/266
Total Debt	$243M	US#2,190/3,121 Sec#92/266
FCF	$-335M	US#2,864/3,121 Sec#238/266
Cash	$165M	US#1,883/3,121 Sec#127/266
Current Ratio	16.95x	US#145/3,121 Sec#37/266
Performance
1Y Return	12.13%	US#1,224/3,121 Sec#160/266
1M Return	-11.29%	US#2,248/3,121 Sec#170/266
From 52W High	-35.84%	US#2,343/3,121 Sec#180/266
1Y MDD	-60.63%	US#2,792/3,121 Sec#216/266
Trading
Volume	4,603,111 shares	US#1,225/3,121 Sec#130/266
Trading Value	$101M	US#1,673/3,121 Sec#128/266
Per Share
EPS	$-3.42	US—/3,121 Sec—/266
BPS	$5.84	US#2,211/3,121 Sec#116/266